SCHEMBL25398403

SCHEMBL25398403

Cc1ccc(-c2nnc(CSc3ccc(O)c(C)c3)s2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QPCTL Q9NXS2 2/20 0.43
QPCT Q16769 1/20 0.43
KDM4E B2RXH2 1/20 0.42
HPGD P15428 1/20 0.42
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
SNCA P37840 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
PPARD Q03181 2/20 0.37
HDAC1 Q13547 2/20 0.36
HDAC2 Q92769 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
TDP1 Q9NUW8 2/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25400529 0.87 PPARD (0.51) QPCTLQPCTPPARD
SCHEMBL25397915 0.87 QPCTL (0.39) QPCTLQPCTKDM4EHPGDALDH1A1
SCHEMBL25399067 0.86 QPCTL (0.43) QPCTLQPCTKDM4EHPGDALDH1A1
SCHEMBL31408959 0.86 QPCTL (0.43) QPCTLQPCTKDM4EHPGDALDH1A1
SCHEMBL25401511 0.84 PPARD (0.49) QPCTLQPCTPPARD
SCHEMBL30579872 0.83 QPCTL (0.41) QPCTLQPCTKDM4EHPGDALDH1A1
SCHEMBL25398951 0.83 QPCTL (0.41) QPCTLQPCTKDM4EHPGDALDH1A1
SCHEMBL31333764 0.81 PPARD (0.54) QPCTLQPCTHPGDALDH1A1MEN1
SCHEMBL25400132 0.81 QPCTL (0.45) QPCTLQPCTKDM4EHPGDPPARD
SCHEMBL25398547 0.80 PPARD (0.59) HPGDALDH1A1MEN1KMT2APPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250197363-A1 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME CUREVERSE INCORPORATED (KR) 2025-06-19 US disclosed
EP-4495106-A1 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME Daegu-Gyeongbuk Medical Innovation Foundation (KR) 2025-01-22 EP disclosed
CN-119212981-A Thiadiazole compound and pharmaceutical composition for preventing or treating inflammatory diseases comprising the same 财团法人 大邱庆北尖端医疗产业振兴财团 2024-12-27 CN disclosed
WO-2023177146-A1 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME 재단법인 대구경북첨단의료산업진흥재단 2023-09-21 WO disclosed
WO-2023177146-A1 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME 재단법인 대구경북첨단의료산업진흥재단 2023-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197363-A1 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME PPARD, PPARG, PPARA QPCTL 2697/4885QPCT 2400/4885KDM4E 3471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.